Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib plus Sintilimab for Advanced Renal Cell Carcinoma
NCT06523049Phase 2Not yet recruiting
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorolanib in renal cell carcinoma (RCC). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
vorolanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06523049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523049.